A Phase 3 interventional study of Vortioxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 92 sites in 17 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2013-12-13.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 836 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 7th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2008, is one of 16 in phase 3, and was the 3rd registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in people who have major depressive disorder (MDD). This study looked at MDD relief in people who took vortioxetine.
The study enrolled 836 patients that had completed one of two other vortioxetine studies. Participants received 5 mg of vortioxetine for the first week of treatment. After completing the first week of treatment, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day based on participant's response as judged by the doctor.
All participants were asked to take one encapsulated tablet at the same time each day throughout the study.
This multi-center trial was conducted worldwide. The overall time to participate in this study was up to 56 weeks. Participants made 13 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition to meeting the exclusion criteria for studies Lu AA21004_304 or Lu AA21004_305 at the time of enrollment into those studies respectively, with the exception of the criteria prohibiting previous exposure to Lu AA21004 and drugs, and the criteria prohibiting patients with increased intraocular pressure, or risk of acute narrow-angle glaucoma, the following exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
Drug: Vortioxetine
Encapsulated vortioxetine immediate-release tablets
Also known as: Lu AA21004, Brintellix®
Physical Examination Findings
Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area. Each system was assessed as normal or abnormal.
Time frame: Baseline and Week 52
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.
Time frame: Weeks 4, 8, 12, 20, 28, 36, 44 and 52
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval \[QTc\]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.
Time frame: Weeks 4, 12, 24, 36 and 52
Number of Participants With Adverse Events (AEs)
The intensity (severity) of each AE was defined as: * Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities. * Moderate: sufficiently uncomfortable to produce some impairment of normal activities. * Severe: incapacitating, preventing the patient from participating in normal activities. The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.
Time frame: From the first dose of open-label study drug until 4 weeks after the last dose (up to 56 weeks)
Number of Participants With Potentially Clinically Significant Vital Sign Findings
Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.
Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52
Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52.
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Time frame: Baseline and Weeks 4, 24 and 52
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Time frame: Baseline and Weeks 4, 24 and 52
Change From Baseline in the Clinical Global Impression of Severity of Illness Scale
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Time frame: Baseline and Weeks 4, 24 and 52
Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).
Time frame: Baseline and Week 52
Change From Baseline to the Final Visit in the Sheehan Disability Scale
The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Time frame: Baseline and Week 52
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Time frame: Baseline and Week 52
Participants took part in the study at 88 investigative sites in Australia, Croatia, France, Germany, Korea, Latvia, Lithuania, Malaysia, The Netherlands, Poland, Russia, Taiwan, Ukraine, and the United States from 17 June 2008 to 23 August 2010.
| Milestone | Vortioxetine |
|---|---|
| Started | 836 |
| Received treatment | 834 |
| Completed | 526 |
| Not completed | 310 |
| Withdrew: Adverse event | 49 |
| Withdrew: Lack of efficacy | 35 |
| Withdrew: Non-compliance with study drug | 28 |
| Withdrew: Protocol deviations | 19 |
| Withdrew: Withdrawal of consent | 81 |
| Withdrew: Lost to follow-up | 59 |
| Withdrew: Other | 39 |
Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area. Each system was assessed as normal or abnormal.
| participants | Vortioxetine |
|---|---|
| Appearance at Baseline: Normal | 758 |
| Appearance at Baseline: Abnormal | 76 |
| Appearance at Week 52: Normal | 484 |
| Appearance at Week 52: Abnormal | 40 |
| Extremities at Baseline: Normal | 806 |
| Extremities at Baseline: Abnormal | 28 |
| Extremities at Week 52: Normal | 511 |
| Extremities at Week 52: Abnormal | 13 |
| Skin at Baseline: Normal | 730 |
| Skin at Baseline: Abnormal | 104 |
| Skin at Week 52: Normal | 465 |
| Skin at Week 52: Abnormal | 59 |
| Head-Neck at Baseline: Normal | 822 |
| Head-Neck at Baseline: Abnormal | 12 |
| Head-Neck at Week 52: Normal | 518 |
| Head-Neck at Week 52: Abnormal | 6 |
| Eyes-Ears-Nose-Throat at Baseline: Normal | 772 |
| Eyes-Ears-Nose-Throat at Baseline: Abnormal | 62 |
| Eyes-Ears-Nose-Throat at Week 52: Normal | 485 |
| Eyes-Ears-Nose-Throat at Week 52: Abnormal | 39 |
| Lungs-Chest at Baseline: Normal | 827 |
| Lungs-Chest at Baseline: Abnormal | 7 |
| Lungs-Chest at Week 52: Normal | 523 |
| Lungs-Chest at Week 52: Abnormal | 1 |
| Heart/Cardiovascular at Baseline: Normal | 816 |
| Heart/Cardiovascular at Baseline: Abnormal | 18 |
| Heart/Cardiovascular at Week 52: Normal | 512 |
| Heart/Cardiovascular at Week 52: Abnormal | 12 |
| Abdomen at Baseline: Normal | 818 |
| Abdomen at Baseline: Abnormal | 12 |
| Abdomen at Baseline: Not done | 4 |
| Abdomen at Week 52: Normal | 515 |
| Abdomen at Week 52: Abnormal | 8 |
| Abdomen at Week 52: Not done | 1 |
| Musculoskeletal at Baseline: Normal | 790 |
| Musculoskeletal at Baseline: Abnormal | 44 |
| Musculoskeletal at Week 52: Normal | 493 |
| Musculoskeletal at Week 52: Abnormal | 31 |
Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.
| participants | Vortioxetine |
|---|---|
| Alanine aminotransferase (ALT) ≥ 3 X ULN | 3 |
| Aspartate aminotransferase (AST) ≥ 3 X ULN | 6 |
| Bilirubin ≥ 34.2 μmol/L | 1 |
| Cholesterol ≥ 7.8 mmol/L | 49 |
| Creatine kinase ≥ 2 X ULN | 80 |
| Creatinine ≥ 175 μmol/L | 1 |
| Glucose ≤ 2.8 mmol/L | 9 |
| Glucose ≥ 13.9 mmol/L | 7 |
| High density lipoprotein cholesterol < 0.9 mmol/L | 102 |
| Low density lipoprotein cholesterol ≥ 5.0 mmol/L | 69 |
| Potassium ≤ 3.0 mmol/L | 0 |
| Potassium ≥ 5.5 mmol/L | 45 |
| Sodium ≤ 125 mmol/L | 1 |
| Sodium ≥ 155 mmol/L | 1 |
| Triglycerides ≥ 3.40 mmol/L | 168 |
| Urate ≤ 0.7 X LLN | 4 |
| Urate ≥ 1.3 XULN | 12 |
| Eosinophils ≥ 0.6 10^9/L | 24 |
| Erythrocytes ≤ 0.9 X LLN | 9 |
| Erythrocytes ≥ 1.1 X ULN | 1 |
| Hematocrit ≤ 0.9 X LLN | 16 |
| Hemoglobin ≤ 0.9 X LLN | 41 |
| Leukocytes ≤ 2.8 X 10^9/L | 10 |
| Leukocytes ≥ 16 X 10^9/L | 3 |
| Lymphocytes ≤ 0.6 X 10^9/L | 5 |
| Lymphocytes ≥ 7 X 10^9/L | 0 |
| Neutrophils ≤ 1.4 X 10^9/L | 26 |
| Neutrophils ≥ 15 X 10^9/L | 2 |
A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval \[QTc\]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.
| participants | Vortioxetine |
|---|---|
| Heart rate ≤50 bpm and change ≤-15bpm | 9 |
| Heart rate ≥120 bpm and change ≥15 bpm | 0 |
| RR interval <500 msec and change ≤-200 msec | 0 |
| RR interval >1200 msec and change ≥200 msec | 13 |
| PR interval <120 msec | 31 |
| PR interval ≥250 msec | 2 |
| QT interval <280 msec | 0 |
| QT interval >500 msec | 2 |
| QTcB <340 msec | 0 |
| QTcB >500 msec | 3 |
| QTcB Change <-60 msec | 6 |
| QTcB Change >60 msec | 4 |
| QTcF <340 msec | 0 |
| QTcF >500 msec | 2 |
| QTcF Change <-60 msec | 3 |
| QTcF Change >60 msec | 2 |
The intensity (severity) of each AE was defined as: * Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities. * Moderate: sufficiently uncomfortable to produce some impairment of normal activities. * Severe: incapacitating, preventing the patient from participating in normal activities. The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.
| participants | Vortioxetine |
|---|---|
| Any adverse event | 589 |
| Related adverse event | 413 |
| Not related adverse event | 176 |
| Mild adverse event | 187 |
| Moderate adverse event | 320 |
| Severe adverse event | 82 |
| Adverse event leading to early termination | 50 |
| Serious adverse event | 29 |
| Serious related adverse event | 5 |
| Serious not related adverse event | 33 |
| Serious adverse event leading to early termination | 11 |
| Deaths | 0 |
Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.
| participants | Vortioxetine |
|---|---|
| SSBP ≤90 mmHg and decrease of ≥20 mmHg | 7 |
| SSBP ≥180 mmHg and increase of ≥20 mmHg | 4 |
| SDBP ≤50 mmHg and decrease of ≥15 mmHg | 1 |
| SDBP ≥105 mmHg and increase of ≥15 mmHg | 8 |
| Supine pulse rate ≤50 bpm and decrease of ≥15 bpm | 7 |
| Supine pulse rate ≥120 bpm and increase of ≥15 bpm | 2 |
| Weight Change of ≥7% weight | 155 |
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
| scores on a scale | Vortioxetine |
|---|---|
| Week 1 (n=805) | -1.1 ± 5.27 |
| Week 2 (n=822) | -3.1 ± 6.10 |
| Week 4 (n=805) | -4.7 ± 7.07 |
| Week 8 (n=752) | -6.5 ± 7.43 |
| Week 12 (n=715) | -7.0 ± 8.27 |
| Week 16 (n=671) | -7.7 ± 8.45 |
| Week 20 (n=639) | -8.4 ± 8.51 |
| Week 24 (n=613) | -8.3 ± 8.92 |
| Week 28 (n=599) | -8.9 ± 8.91 |
| Week 36 (n=568) | -9.3 ± 9.05 |
| Week 44 (n=540) | -9.6 ± 9.32 |
| Week 52 (n=522) | -10.0 ± 8.86 |
| Final Visit (n=829) | -7.9 ± 9.66 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
| scores on a scale | Vortioxetine |
|---|---|
| Week 4 (n=818) | -4.5 ± 7.38 |
| Week 24 (n=642) | -7.9 ± 9.24 |
| Week 52 (n=526) | -9.5 ± 8.90 |
| Final Visit (n=818) | -7.4 ± 9.81 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
| scores on a scale | Vortioxetine |
|---|---|
| Week 4 (n=818) | -2.9 ± 5.12 |
| Week 24 (n=642) | -5.1 ± 6.44 |
| Week 52 (n=527) | -6.6 ± 6.38 |
| Final Visit (n= 818) | -5.2 ± 6.76 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
| scores on a scale | Vortioxetine |
|---|---|
| Week 4 (n=818) | -0.53 ± 1.002 |
| Week 24 (n=642) | -0.98 ± 1.295 |
| Week 52 (n= 527) | -1.33 ± 1.266 |
| Final Visit (n=818) | -1.00 ± 1.338 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).
| scores on a scale | Vortioxetine |
|---|---|
| Physical functioning subscore (n=824) | 4.5 ± 15.88 |
| Role-physical subscore (n=824) | 8.1 ± 25.51 |
| Bodily pain subscore (n=824) | 4.9 ± 24.29 |
| General health subscore (n=823) | 6.4 ± 18.38 |
| Vitality subscore (n=824) | 10.1 ± 23.03 |
| Social functioning subscore (n=824) | 10.9 ± 26.90 |
| Role-emotional subscore (n=824) | 12.3 ± 28.24 |
| Mental health subscore (n=824) | 10.7 ± 22.04 |
The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
| scores on a scale | Vortioxetine |
|---|---|
| Change From Baseline to the Final Visit in the Sheehan Disability Scale | -4.6 ± 8.01 |
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
| participants | Vortioxetine |
|---|---|
| Baseline: Any resource use | 137 |
| Baseline: Any hospitalization-related services | 4 |
| Baseline: Hospitalization related to depression | 0 |
| Baseline: Any sick leave | 53 |
| Baseline: Sick leave related to depression | 42 |
| Week 52: Any resource use | 138 |
| Week 52:Any hospitalization-related services | 7 |
| Final Visit: Hospitalization related to depression | 0 |
| Week 52: Any sick leave | 41 |
| Week 52: Sick leave related to depression | 25 |
Collected over From first dose of study until 30 days after the last dose.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine | — | 29/834 (3.5%) | 452/834 (54.2%) |
| Event | Vortioxetine |
|---|---|
| InfluenzaInfections and infestations | 2/834 |
| Suicidal ideationPsychiatric disorders | 2/834 |
| AnemiaBlood and lymphatic system disorders | 1/834 |
| Atrial fibrillationCardiac disorders | 1/834 |
| Coronary artery diseaseCardiac disorders | 1/834 |
| Myocardial infarctionCardiac disorders | 1/834 |
| Supraventricular tachycardiaCardiac disorders | 1/834 |
| TachycardiaCardiac disorders | 1/834 |
| Tachycardia paroxysmalCardiac disorders | 1/834 |
| Umbilical hernia, obstructiveGastrointestinal disorders | 1/834 |
| Event | Vortioxetine |
|---|---|
| NauseaGastrointestinal disorders | 127/834 |
| HeadacheNervous system disorders | 102/834 |
| NasopharyngitisInfections and infestations | 82/834 |
| DiarrhoeaGastrointestinal disorders | 60/834 |
| DizzinessNervous system disorders | 57/834 |
| Upper respiratory tract infectionInfections and infestations | 53/834 |
| Weight increasedInvestigations | 36/834 |
| InfluenzaInfections and infestations | 33/834 |
| SomnolenceNervous system disorders | 33/834 |
| Back painMusculoskeletal and connective tissue disorders | 32/834 |
| Age Continuous(Years) | Vortioxetine |
|---|---|
| Mean | 45.5 ± 12.78 |
| Age, Customized(Participants) | Vortioxetine |
|---|---|
| ≤55 years | 636 |
| >55 years | 200 |
| Sex: Female, Male(Participants) | Vortioxetine |
|---|---|
| Female | 526 |
| Male | 310 |
| Race/Ethnicity, Customized(Participants) | Vortioxetine |
|---|---|
| Caucasian (White, including Hispanic) | 693 |
| Black | 86 |
| Asian | 54 |
| American Indian or Alaska Native | 2 |
| Native Hawaiian/ Other Pacific Islander | 1 |
| Race/Ethnicity, Customized(Participants) | Vortioxetine |
|---|---|
| Hispanic/Latino | 53 |
| Non-Hispanic/Non-Latino | 782 |
| Missing | 1 |
| Region of Enrollment(Participants) | Vortioxetine |
|---|---|
| Australia | 4 |
| Germany | 207 |
| France | 11 |
| Croatia | 11 |
| Republic of Korea | 25 |
| Lithuania | 10 |
| Latvia | 20 |
| Malaysia | 17 |
| Netherlands | 7 |
| Poland | 57 |
| Russia | 40 |
| Taiwan | 3 |
| Ukraine | 37 |
| United States | 387 |
| Weight(kg) | Vortioxetine |
|---|---|
| Mean | 81.16 ± 20.829 |
| Height(cm) | Vortioxetine |
|---|---|
| Mean | 169.00 ± 9.777 |
5 further baseline measures are reported on the registry.
The record gives a start of Jun 2008, a primary completion of Jul 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine